Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576923 | 1.00 | HTR1D (0.41) | HTR1DPDE5ABACE1CSNK2A1CSNK2A2 | |
| SCHEMBL23577125 | 0.88 | PDE5A (0.42) | PDE5ACSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL29909612 | 0.87 | KDR (0.38) | HTR1DPDE5ABACE1KDRPDGFRB | |
| SCHEMBL23576624 | 0.87 | KDR (0.38) | HTR1DPDE5ABACE1KDRPDGFRB | |
| SCHEMBL23577302 | 0.86 | HTR6 (0.39) | PDE5A | |
| SCHEMBL23601533 | 0.84 | SMN1; SMN2 (0.40) | PDE5A | |
| SCHEMBL29909858 | 0.83 | CSNK2A1 (0.36) | HTR1DPDE5ACSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL23577892 | 0.83 | CSNK2A1 (0.36) | HTR1DPDE5ACSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL23577176 | 0.82 | ABCG2 (0.47) | PDE5A | |
| SCHEMBL29909329 | 0.82 | ABCG2 (0.47) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | HTR1D 4084/4885PDE5A 1924/4885BACE1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.